| アブストラクト | This study aims to figure out the worldwide prevalence of anticancer therapy-associated acute kidney injury (AKI) and tubulointerstitial nephritis (TIN) and the relative risk of each cancer drug. We conducted an analysis of VigiBase, the World Health Organization pharmacovigilance database, 1967-2023 via disproportionate Bayesian reporting method. We further categorized the anticancer drugs into four groups: cytotoxic therapy, hormone therapy, immunotherapy, and targeted therapy. Reporting odds ratio (ROR) and information component (IC) compares observed and expected values to investigate the associations of each category of anticancer drugs with AKI and TIN. We identified 32,722 and 2056 reports (male, n = 17,829 and 1,293) of anticancer therapy-associated AKI and TIN, respectively, among 4,592,036 reports of all-drug caused AKI and TIN. There has been a significant increase in reports since 2010, primarily due to increased reports of targeted therapy and immunotherapy. Immunotherapy exhibited a significant association with both AKI (ROR: 8.92; IC(0.25): 3.06) and TIN (21.74; 4.24), followed by cytotoxic therapy (7.14; 2.68), targeted therapy (5.83; 2.40), and hormone therapy (2.59; 1.24) for AKI, and by cytotoxic therapy (2.60; 1.21) and targeted therapy (1.54; 0.61) for TIN. AKI and TIN were more prevalent among individuals under 45 years of age, with a female preponderance for AKI and males for TIN. These events were reported in close temporal relationship after initiation of the respective drug (16.53 days for AKI and 27.97 days for TIN), and exhibited a high fatality rate, with 23.6% for AKI and 16.3% for TIN. These findings underscore that kidney-related adverse drug reactions are of prognostic significance and strategies to mitigate such side effects are required to optimize anticancer therapy. |
|---|
| 投稿者 | Yoon, Soo-Young; Lee, Sooji; Lee, Kyeongmin; Kim, Jin Sug; Hwang, Hyeon Seok; Kronbichler, Andreas; Jacob, Louis; Shin, Ju-Young; Lee, Jin A; Park, Jaeyu; Lee, Hyeri; Lee, Hayeon; Jeong, Kyunghwan; Yon, Dong Keon |
|---|
| 組織名 | Division of Nephrology, Department of Internal Medicine, Kyung Hee University;Hospital, Kyung Hee University College of Medicine, Seoul, South Korea.;Department of Medicine, Kyung Hee University College of Medicine, Seoul, South;Korea.;Center for Digital Health, Medical Science Research Institute, Kyung Hee;University College of Medicine, Seoul, South Korea.;Department of Regulatory Science, Kyung Hee University, Seoul, South Korea.;Department of Internal Medicine IV, Nephrology and Hypertension, Medical;University Innsbruck, Innsbruck, Austria.;Research and Development Unit, Parc Sanitari Sant Joan de Deu, CIBERSAM, ISCIII,;Barcelona, Spain.;Department of Physical Medicine and Rehabilitation, Lariboisiere-Fernand Widal;Hospital, AP-HP, Universite Paris Cite, Paris, France.;Epidemiology of Ageing and Neurodegenerative Diseases (EpiAgeing), Inserm U1153,;Universite Paris Cite, Paris, France.;School of Pharmacy, Sungkyunkwan University, Suwon, South Korea.;Department of Biomedical Engineering, Kyung Hee University, Yongin, Korea.;University College of Medicine, Seoul, South Korea. wwhy28@khu.ac.kr.;wwhy28@khu.ac.kr.;khjeong@khu.ac.kr.;Korea. yonkkang@gmail.com.;University College of Medicine, Seoul, South Korea. yonkkang@gmail.com.;yonkkang@gmail.com.;Department of Pediatrics, Kyung Hee University Medical Center, Kyung Hee;University College of Medicine, 23 Kyungheedae-Ro, Dongdaemun-Gu, Seoul, 02447,;Republic of Korea. yonkkang@gmail.com. |
|---|
